Reimagining Medicine Q2 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Conclusions
Appendix
Innovation: Clinical trials
H1 growth driven by strong performance from EntrestoⓇ
KesimptaⓇ, PluvictoⓇ and KisqaliⓇ
H1 sales
Entresto
Sales
USD million
Growth vs. PY
USD million
2,915
sacubitri/valsartan
Kesimpta
873
(ofatumumab)
PLUVICTO™
451
KISQALI
908
361
ribociclib
SCEMBLIX®
182
126
(asciminib)
LEQVIO®
142
106
PROMACTA®
1,130
105
(eltrombopag)
Tafinlar. Mekinist.
954
99
299
Adanie LUTATHERA
88
PIQRAY
246
(alpelisib) tablets
88
ILARIS
(canakinumab)
rolex
644
84
Growth vs. PY
CC
697
35%
439
439
References
Abbreviations
GROWTH
103%
nm
Strong growth
(+69% cc);
73%
expected to continue
228%
293%
13%
15%
43%
57%
18%
Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
nm not meaningful.
38 Investor Relations | Q2 2023 Results
U NOVARTIS | Reimagining MedicineView entire presentation